Definitions of, Advances in, and Treatment Strategies for Breast Cancer Oligometastasis

Area of Science:

• Oncology
• Radiotherapy
• Medical Imaging

Background:

• Oligometastasis, a state of limited metastatic disease, presents a therapeutic challenge in breast cancer.
• Initial trials suggested survival benefits for local aggressive treatments, but breast cancer data was limited.
• Subsequent breast cancer-specific trials yielded inconclusive survival benefits, necessitating improved patient selection and systemic therapy integration.

Purpose of the Study:

• To review current definitions, evidence, and therapeutic considerations for oligometastatic breast cancer.
• To explore the evolving understanding of oligometastasis, including its potential as a distinct biological subtype.
• To outline future research directions for optimizing treatment strategies.

Main Methods:

• Review of existing clinical trials (e.g., SABR-COMET, NRG-BR002) and scientific literature.
• Analysis of evolving definitions incorporating radiological, clinical, and biological features.
• Exploration of advances in imaging, molecular profiling (e.g., PIK3CA, YAP/TAZ), and circulating tumor DNA (ctDNA).

Main Results:

• Oligometastatic breast cancer may represent a distinct subtype with potential biomarkers.
• Organ-specific local therapies (radiotherapy, surgery, proton therapy) show local control but require further survival data.
• Circulating tumor DNA (ctDNA) analysis is emerging for improved patient selection and monitoring.

Conclusions:

• Refined patient selection and integration of local and systemic therapies are crucial for oligometastatic breast cancer.
• Further research, including ongoing trials, is needed to establish definitive survival benefits.
• Understanding the biological underpinnings and leveraging advanced techniques will guide future treatment optimization.